07:48 AM EST, 11/11/2024 (MT Newswires) -- NuCana ( NCNA ) said Monday that initial data from an ongoing Phase 1b/2 study of NUC-3373 in combination with pembrolizumab indicated a significant reduction in tumor volume in patients with lung cancer.

"NUC-3373 may be an attractive alternative to pemetrexed in patients with NSCLC and mesothelioma," David Harrison, NuCana's ( NCNA ) head of translational medicine, said in a release. "Observing that NUC-3373 in combination with docetaxel is stabilizing disease in these hard-to-treat patient populations provides further evidence supporting this hypothesis."